NCT00329693已完成2 期
A Randomised, Double-blind, Parallel Groups, Dose-finding, Placebo-controlled, Multi-centre, Proof of Concept Study Assessing the Effect of 3-wk Treatment With 1 of 3 Oral Doses of Quinagolide & Placebo in Preventing Ovarian Hyperstimulation Syndrome in Women Undergoing Controlled Ovarian Hyperstimulation.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 182
- 试验地点
- 7
- 主要终点
- OHSS
研究概览
简要总结
Women included in this study are undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (ART) and present with signs of moderate risk of developing OHSS.
详细描述
No data to be entered.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Care Provider)
入排标准
- 年龄范围
- 21 Years 至 37 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
1
Placebo Comparator
Daily Tablets Dosing
干预措施: Norprolac (Drug)
2
Experimental
Daily Tablets Dose
干预措施: Norprolac (Drug)
3
Experimental
Daily Tablets Dosing
干预措施: Norprolac (Drug)
4
Experimental
Daily Tablets Dosing
干预措施: Norprolac (Drug)
结局指标
主要结局
OHSS
时间窗: 41 days after hCG injection
次要结局
未报告次要终点
研究者
研究点 (7)
Loading locations...
相似试验
已完成
1 期
Study in Healthy Young Women to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of VilaprisanClinical Trial, Phase INCT02262663Bayer70
已完成
4 期
Role of Myo-inositol and D-chiro-inositol on Oocyte QualityInfertilityNCT01338844AGUNCO Obstetrics and Gynecology Centre
进行中（未招募）
2 期
A Trial of Vigil for Participants With Ovarian CancerOvarian NeoplasmsOvarian CancerNCT02346747Gradalis, Inc.92
已完成
4 期
CONSORT Randomized Controlled Trial in Assisted Reproductive TechnologyInfertilityNCT00829244Merck KGaA, Darmstadt, Germany200
已完成
3 期
Casodex vs Placebo in Non-Metastatic Early Prostate CancerNon-Metastatic Prostate CancerNCT00672282AstraZeneca1,218